Stage IIIB ER/PR-positive breast cancer: emergency mastectomy for infected fungating tumor

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: ER >75%; PR >75%; HER2 0 / HER2-negative; grade 3 invasive ductal carcinoma

As of May 2025, management centered on anastrozole after emergency mastectomy, repeated debridements, wound care, and major postoperative complications; oncology follow-up had become inconsistent because of ongoing medical setbacks.

PubMed CentralRead more →

Stage III HR-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-positive

Three years after diagnosis, Christine described herself in the survivorship stage and focused on the physical and emotional effects that continued after active treatment.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of May 2025, Kelsey had completed chemotherapy, double mastectomy with reconstruction, and 16 radiation sessions, and was continuing tamoxifen with Verzenio planned for 2 years plus Lupron ovarian-suppression shots.

The Patient StoryRead more →

Breast cancer first discovered after it had already spread to the spinal cord

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Estrogen receptor-positive; progesterone receptor-negative; HER2 score 0

Metastatic Site: intramedullary spinal cord (D11-D12); bilateral…

Her paraplegia did not improve after spinal radiation, and she died from disease progression 3 months after the breast-cancer diagnosis.

PubMed CentralRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: LaShae's Patient Story

Patient Info: LaShae, Female, Under 40 | Stage II

Biomarkers: ER-positive; comprehensive genetic panel negative

As of May 2025, LaShae had completed mastectomy for Stage IIB ER-positive breast cancer with 2 positive lymph nodes and was undergoing chemotherapy, with radiation and 5-10 years of hormone therapy planned.

The Patient StoryRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Rib; spine; pelvis

After a mixed response on the radium trial, Samantha changed to anastrozole and abemaciclib. She described the newer hormone-targeted combination as easier to tolerate and working better while remaining in ongoing treatment.

The Patient StoryRead more →

Stage IA ER/PR-positive breast cancer in SLE: arm-behind-back radiation after lumpectomy

Patient Info: Anonymized, Female, 40s | Stage I

Biomarkers: ER >95%; PR >95%; HER2 1+; Ki-67 23%; no BRCA1/2 variants identified

As of April 2025, 15 months after 3D conformal radiotherapy, she had no local recurrence, no distant metastasis, and no radiation pneumonitis.

PubMed CentralRead more →

Primary neuroendocrine breast tumor: disease-free 5 years after mastectomy and tamoxifen

Patient Info: Anonymized, Female, 50s

Biomarkers: Neuroendocrine breast tumor: ER/PR positive, HER2 negative

As of April 2025, she had remained disease-free for 5 years after mastectomy, negative sentinel lymph node biopsy, and tamoxifen 20 mg once daily.

PubMed CentralRead more →

Stage IIA ER-positive breast cancer with axillary tuberculosis: no metabolically active disease after treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER 78% positive; PR-negative; HER2/neu-negative; Ki-67 21%; Luminal A subtype

As of April 2025, follow-up PET-CT showed no metabolically active disease after mastectomy, adjuvant anthracycline-based chemotherapy, letrozole, and 6 months of anti-tuberculosis therapy.

PubMed CentralRead more →

Stage I HR-Positive Invasive Lobular Carcinoma: Mandy's Patient Story

Patient Info: Mandy, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; low Oncotype score; genetic testing negative for 70 cancer-causing genes

As of April 2025, Mandy was about 10 months after bilateral mastectomy for Stage IA ER-positive, PR-positive ILC, had a low Oncotype score, was planning several years of tamoxifen, and was still in reconstruction.

Lobular Breast Cancer AllianceRead more →

Early-stage mixed breast carcinoma found during LGI1 limbic encephalitis workup

Patient Info: Anonymized, Female | Stage I

Biomarkers: ER 95-100% positive; PR 80% positive; HER2-negative

She gradually recovered after immunotherapy for limbic encephalitis and excision of the early-stage breast tumor, and had returned to part-time work 12 months after discharge.

PubMed CentralRead more →

Breast cancer linked to a rare kidney condition believed to be cancer-related

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2 score 1+; Ki-67 5-10%

At the latest follow-up, she had no local or distant breast-cancer recurrence and maintained excellent performance status.

PubMed CentralRead more →

HER2-positive breast cancer with brain metastases: responding well to T-DXd

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive / HER2 IHC 3+

Metastatic Site: brain (left cerebellum, left frontal lobe, medulla)

After 14 months and 19 doses of T-DXd, brain metastases remained controlled with no symptomatic or radiological relapse and no severe T-DXd-related adverse events.

PubMed CentralRead more →

HER2-Positive Invasive Ductal Breast Cancer Treated After Chemotherapy-Related Hemorrhagic Cystitis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive, PR-positive, HER2-positive

Under surveillance for 2 years with no signs of malignancy.

PubMed CentralRead more →

Ductal Carcinoma In Situ With Persistent Vaccine-Related Lymph Node Swelling

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive, PR-positive

Recovered uneventfully after mastectomy, with no additional cancer treatment given.

PubMed CentralRead more →

Accessory breast cancer: surgery, radiation, endocrine therapy, no recurrence

Patient Info: Anonymized, Female, 50s | Stage I

Biomarkers: ER 2+/>95%; PR 3+/>95%; HER2-negative; Ki-67 2%

As of March 2025, 26 months after surgery, she continued anastrozole and breast MRI showed no evidence of recurrence.

PubMed CentralRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Katie's Patient Story

Patient Info: Katie, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; genetic testing negative

As of February 2025, Katie was a few months beyond active treatment for Stage III ER-positive, PR-positive, HER2-negative ILC and was adjusting to maintenance therapy with Verzenio, Lupron, and Letrozole.

Lobular Breast Cancer AllianceRead more →

Metastatic Breast Cancer Returning About 20 Years After Initial Treatment

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-positive

Metastatic Site: bones

About 20 years after her original breast-cancer treatment and sustained remission, bone biopsy confirmed metastatic recurrence; she became too unwell for planned cancer therapy and chose supportive care.

PubMed CentralRead more →

Metastatic Lobular Breast Cancer First Appearing as Skin Nodules

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-negative

Metastatic Site: skin

Died 7 months after the diagnosis of cutaneous metastatic breast cancer.

PubMed CentralRead more →

Stage II HR-Positive Invasive Lobular Carcinoma: Karen's Survivor Story

Patient Info: Karen, Female, 40s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative; grade 2; inherited genetic testing negative

Karen completed double mastectomy, 3 months of chemotherapy and reconstruction. She was doing well on ongoing endocrine and targeted therapy and walking 3–5 miles daily.

Lobular Breast Cancer AllianceRead more →

Stage I ER-positive/HER2-positive breast cancer with radiation-associated morphea

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: ER-positive; PR-negative; HER2-positive

No evidence of breast cancer recurrence after 2018 treatment; ongoing issue was generalized morphea and breast deformity related to prior radiation, improved with mycophenolate by April 2024.

PubMed CentralRead more →

Breast Cancer Responses During Mistletoe Extract and Intratumoral Influenza Vaccine Treatment — Case 1

Patient Info: Anonymized, female, 60s

Biomarkers: Initial ER 100%, PR 60%, HER2-negative; recurrence ER 100%

She remained in remission 3 years after surgery for the local recurrence.

PubMed CentralRead more →

Breast Cancer Responses During Mistletoe Extract and Intratumoral Influenza Vaccine Treatment

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: bone, lungs, pleura

After a mixed radiologic response, she declined further imaging and remained in good condition without clinical evidence of further progression.

PubMed CentralRead more →

Stage IIIA encapsulated papillary breast carcinoma with invasion: mastectomy, axillary dissection, and anastrozole

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: ER 100%; PgR 80%; HER2 2+ by IHC with FISH negative; Ki-67 20%; initial biopsy HER2 1+

She received postoperative anastrozole alone after right mastectomy and axillary dissection; no apparent recurrence was observed 18 months after surgery.

PubMed CentralRead more →